{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":31,"cheight":54,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"//oss.xinghuo86.cn/649785920978944/670337255604299.png","picWidth":31,"picHeight":52,"inpColor":"","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

专业的糖尿病医院

{"img":"","passBy":"0","picBd":"0","size":"1","bdSize":"1","cwidth":44,"cheight":48,"picBdRadio":"0","borderType":"solid","jump":"0","definedUrl":"","isPicBd":"0","effectBdLine":"solid","image":"//oss.xinghuo86.cn/649785920978944/670337255604300.png","picWidth":44,"picHeight":48,"inpColor":"","color":"#000000","type":0,"effectBdColor":"#000000","hasEdit":true}

咨询热线:

400-737-1111  0851-8811-4040

贵州百灵集团关于抗肿瘤化药1.1类新药GZ50研发项目的进展公告
发布日期:2015-05-25 22:51:54浏览量:373
贵州百灵集团关于抗肿瘤化药1.1类新药GZ50研发项目的进展公告

本公司及董事会全体成员保证公告内容真实、准确和完整,公告不存在虚假记载、误导性陈述或者重大遗漏。
    风险提示:
    鉴于药物研发的复杂性、风险性和不确定性,各阶段研究均具有风险性,公司将及时履行信息披露义务,请投资者注意投资风险。
    1、本研究项目